Last updated: February 27, 2026
What is the drug associated with NDC 51660-0754?
The National Drug Code (NDC) 51660-0754 corresponds to Leqembi (lecanemab-irmb), an amyloid beta-directed antibody developed by Eisai and Biogen. It is approved for the treatment of early Alzheimer's disease.
What is the current market landscape for lecanemab?
Regulatory Status and Approval Timeline
- FDA Approval Date: July 6, 2023
- Indication: Treatment of Alzheimer’s disease in early stages characterized by confirmed amyloid beta pathology
- Approval Pathway: Accelerated approval based on reduction in amyloid beta plaques; confirmatory trials required for full approval
Competitive Environment
- Main Competitors: Aduhelm (aducanumab), developed by Biogen; Lecanemab is positioned as a potentially more effective option with better safety profile
- Other Drugs: Donanemab (Eli Lilly), gantenerumab (Hoffmann-La Roche), and emerging therapies under development
Market Size and Demand Drivers
- Alzheimer’s Disease Prevalence: Over 6 million Americans aged 65+ with Alzheimer’s; expected to rise to 13 million by 2050
- Treatment Penetration: Early adoption driven by FDA approval and payer coverage
- Pricing Sensitivity: Payers and healthcare providers scrutinize cost-benefit ratio, especially for high-cost biologics
Pricing and Reimbursement
- List Price: Approximately $26,500 per year (initial estimates at FDA approval)
- Reimbursement Dynamics: CMS and private insurers evaluate clinical benefit, cost-effectiveness, and impact on healthcare system
- Patient Access: Potential barriers include high out-of-pocket costs, requirement for PET imaging pre-treatment, and infusion costs
What are the price projections based on current trends?
Short-Term Price Expectations (Next 12-24 months)
- Stable List Price: Expect little variation around $26,500 per year, as initial pricing reflects research, development, and manufacturing costs
- Payer Negotiations: Insurers may negotiate discounts or impose utilization controls, potentially reducing effective patient cost
Mid to Long-Term Price Trends (Next 3-5 years)
- Potential Price Adjustments: If biosimilar or alternative therapies emerge, biosimilar development could pressure prices downward
- Market Penetration Impact: Increased adoption may lead Eisai and Biogen to explore volume-based discounts
- Drug Lifecycle Factors: Competitive pressures may influence future pricing strategies, especially if additional indications received regulatory approval
Cost-Effectiveness and Value-Based Pricing
- Several studies evaluate lecanemab's clinical efficacy versus costs. Clinical trial data suggests a slowing of cognitive decline, which could justify premium pricing if long-term benefits translate into healthcare savings
What are the key factors influencing future price movements?
| Factor |
Impact |
Notes |
| Regulatory approvals |
Price stability or increase |
Approval of broader indications could allow higher prices |
| Competitive landscape |
Possible price decline |
Entry of biosimilars or new drugs may pressure prices |
| Clinical efficacy |
Justifies premium |
Better outcomes increase willingness-to-pay |
| Healthcare policy |
Pricing negotiations |
Payer policies influence net prices and access |
What are the revenue projections?
- Assuming initial market penetration reaches 10% of eligible early Alzheimer’s patients within 5 years:
| Metric |
Assumption |
Estimated Revenue (USD) |
Notes |
| Eligible Patients |
1 million globally |
100,000 patients |
Conservative estimate based on disease prevalence |
| Adoption Rate |
10% |
10,000 patients |
Gradual uptake over 5 years |
| Revenue per Patient |
$26,500/year |
$265 million/year |
Initial list price |
- Global expansion may double this revenue, contingent on approval and insurance coverage in other markets
Key Takeaways
- NDC 51660-0754 (Leqembi) entered the market in 2023 as a targeted therapy for early Alzheimer’s
- List price is approximately $26,500 annually, with potential downward pressure from market competition and biosimilar development
- Short-term projections expect stable pricing; long-term depends on regulatory approvals, clinical outcomes, and payer negotiations
- The market size is driven by increasing Alzheimer’s prevalence, with significant revenue potential if adoption accelerates
- Cost-effectiveness evidence will shape payer coverage and patient access, affecting pricing strategies
FAQs
1. How does lecanemab compare to other Alzheimer’s treatments?
Lecanemab demonstrates greater reduction in amyloid beta plaques and slower cognitive decline than some competitors, with a favorable safety profile.
2. What barriers could impact the adoption of lecanemab?
High treatment costs, requirement for expensive imaging, infusion logistics, and payer coverage decisions limit immediate widespread use.
3. Are biosimilars expected for lecanemab?
Biosimilar development is unlikely in the near term due to patent protections and complex biologic manufacturing, but could influence prices in the future.
4. What factors could lead to price reductions?
Entry of new competitors, clinical trial results showing limited benefits, or policy changes favoring cost containment could reduce prices.
5. How could future regulatory decisions influence pricing?
Broader approvals, such as for additional indications, could justify higher prices; restrictions or unfavorable rulings could limit profitability.
References
- Food and Drug Administration. (2023). FDA approves first drug for early Alzheimer’s.
- Eisai and Biogen. (2023). Leqembi (lecanemab-irmb) prescribing information.
- MarketWatch. (2023). Alzheimer’s drug market analysis report.
- IQVIA. (2023). U.S. pharmaceutical pricing and reimbursement data.
- Alzheimer’s Association. (2022). Alzheimer's disease facts and figures.
